Presented at the Gerontological Society of America, November 20, 2009, Atlanta, Georgia.
Serum 25-Hydroxyvitamin D, Transitions Between Frailty States, and Mortality in Older Adults: The Invecchiare in Chianti Study
Article first published online: 27 JAN 2012
© 2012, Copyright the Authors Journal compilation © 2012, The American Geriatrics Society
Journal of the American Geriatrics Society
Volume 60, Issue 2, pages 256–264, February 2012
How to Cite
Shardell, M., D'Adamo, C., Alley, D. E., Miller, R. R., Hicks, G. E., Milaneschi, Y., Semba, R. D., Cherubini, A., Bandinelli, S. and Ferrucci, L. (2012), Serum 25-Hydroxyvitamin D, Transitions Between Frailty States, and Mortality in Older Adults: The Invecchiare in Chianti Study. Journal of the American Geriatrics Society, 60: 256–264. doi: 10.1111/j.1532-5415.2011.03830.x
- Issue published online: 14 FEB 2012
- Article first published online: 27 JAN 2012
- Italian Ministry of Health
- U.S. National Institute on Aging Intramural Research. Grant Numbers: 263 MD 916413, 263 MD 821336
- Procter and Gamble. Grant Numbers: R01 AG027012, K25 AG034216, T32 AG00262, K12HD04389, K23AG027746, K12HD055931, R21HD057274, R01 HL094507
- National Institutes of Health
- Geriatrics and Gerontology Education and Research Program
- vitamin D
To assess whether serum 25-hydroxyvitamin D (25(OH)D) concentrations relate to transitions between the states of robustness, prefrailty, and frailty and to mortality in older adults.
The Invecchiare in Chianti (InCHIANTI) Study, a prospective cohort study.
Adults aged 65 and older (N = 1,155).
Serum 25(OH)D concentrations measured at baseline; frailty state (robust, prefrail, frail) assessed at baseline and 3 and 6 years after enrollment; and vital status determined 3 and 6 years after enrollment.
The median (interquartile range) 25(OH)D concentration was 16.0 ng/mL (10.4–25.6 ng/mL; multiply by 2.496 to convert to nmol/L). Prefrail participants with 25(OH)D levels less than 20 ng/mL were 8.9% (95% confidence interval (CI) = 2.5–15.2%) more likely to die, 3.0% (95% CI = −5.6–14.6%) more likely to become frail, and 7.7% (95% CI = −3.5–18.7%) less likely to become robust than prefrail participants with 25(OH)D levels of 20 ng/mL or more. In prefrail participants, each 5-ng/mL decrement of continuous 25(OH)D was associated with 1.46 times higher odds of dying (95% CI = 1.18–2.07) and 1.13 higher odds of incident frailty (95% CI = 0.90–1.39) than with recovery of robustness. Transitions from robustness or frailty were not associated with 25(OH)D levels.
Results provide evidence that prefrailty is an “at risk” state from which older adults with high 25(OH)D levels are more likely to recover than to decline, but high 25(OH)D levels were not associated with recovery from frailty. Thus, 25(OH)D levels should be investigated as a potential therapy to treat prefrailty and prevent further decline.